Akums Drugs and Pharmaceuticals Limited

NSE: AKUMSHealthcare

Akums Drugs and Pharmaceuticals Limited Share Price & Analysis

₹765.75−1.90%Updated 4 Sept 2026, 03:30 pm IST
LTP
₹765.75−1.90%
Open
₹776.75
High
₹776.75
Low
₹750.80
Close
₹765.75
52W High
₹797.00
52W Low
₹409.00
Volume
339K
Lot Size
1
Sector
Healthcare
Market Cap
₹12K Cr
Face Value
₹2
Mid Cap

Price Chart

Candle
Range

Fundamentals

P/E
39.50
Sector P/E
54.70
P/B
2.45
EPS
₹16.68
ROE
8.45%
ROCE
14.90%
D/E Ratio
0.05
Div Yield
0.13%
Book Value
₹211.00

Strengths

  • Attractively valued vs sector (P/E 39.5x vs industry 54.7x)
  • Virtually debt-free

Concerns

  • Trading near 52-week high (₹797)

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
1,899
₹4.6L Cr36.15.461620.50.07
DIVISLAB
Divi's Laboratories Limited
9,100
₹2.4L Cr81.114.4216.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
4,857
₹1.8L Cr82.819.5827.415.20.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,650
₹1.2L Cr59.113.1321.217.40.88
CIPLA
Cipla Limited
1,385
₹1.1L Cr31.33.2511.615.50.01
ZYDUSLIFE
Zydus Lifesciences Limited
1,120
₹1.1L Cr234.1621.221.10.38
LAURUSLABS
Laurus Labs Limited
1,840
₹99K Cr90.918.7418.317.80.46

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

AKUMS · as of Jun 2026

Promoters75.26%
FII1.91%0.53pp
DII13.44%0.92pp
Public6.67%0.38pp
Others2.73%
CategoryMar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters75.26%75.26%75.26%75.26%75.26%75.26%
FII5.77%4.24%2.27%1.14%1.38%1.91%
DII7.39%8.85%9.28%14.41%14.36%13.44%
Public8.84%8.92%10.46%6.45%6.29%6.67%
Others2.73%2.73%2.73%2.73%2.73%2.73%

Corporate Events

Intimation of Board Meeting

Board Mtg7 Aug 2026

Dividend - Re 1 Per Share/Special Dividend - Rs 2 Per Share

Dividend2 Jul 2026

Latest News

All news

Akums receives ESG rating update

*Akums receives ESG rating update.* The company has disclosed its latest ESG rating in a regulatory filing. This non-financial assessment reflects sustainability and governance practices. **No immediate financial impact** is expected. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG

NSE Filing3d ago
Low Impact

Akums to host investor meet on August 25, 2026

*Akums to host investor meet on August 25, 2026.* The company announced the schedule for its analyst and institutional investor meet. **No financial updates or major announcements** were disclosed in the filing. It is a routine corporate communication ahead of the event. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet

NSE Filing24 Aug
Low Impact

Akums to host analyst and investor meet.

*Akums to host analyst and investor meet.* The event is scheduled to provide updates to institutional investors and analysts. No financial announcements or major developments were indicated. It’s a routine engagement to maintain investor relations. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet

NSE Filing13 Aug
Low Impact

Akums hosts investor call; no major announcements.

*Akums hosts investor call; no major announcements.* The company shared updates during its analyst and institutional investor meet, though no significant financial or operational disclosures were made. Transcript available via NSE corporate filing. Business outlook remains stable with no changes to guidance. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorCall

NSE Filing13 Aug
Low Impact

Akums publishes mandatory newspaper notice

*Akums publishes mandatory newspaper notice.* This is a routine corporate disclosure as required by regulatory norms. No financial or operational updates were provided. Such filings are standard and do not impact business operations. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling

NSE Filing10 Aug
Low Impact

Akums acquires Oriflame India's unit for ₹56 crore

*Akums acquires Oriflame India's manufacturing unit for ₹56 crore.* This marks a strategic diversification beyond pharmaceuticals into FMCG manufacturing. The move expands Akums’ production capabilities and client base in contract manufacturing. **₹56 crore** investment underscores growing vertical integration ambitions. 📊 *STOCKS:* $AKUMS | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #Acquisition

eHealth Magazine30 Jul
Medium Impact

Akums to hold 22nd Annual General Meeting

*Akums to hold 22nd Annual General Meeting* as per a newspaper publication notice. The AGM is a routine annual event for shareholders. No major corporate announcements were disclosed in the filing. Details on dividends or key resolutions are awaited. 📊 *STOCKS:* AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM

NSE Filing19 Jun
Low Impact

Akums shares to see e-voting updates for FY2025-26

*Akums shares to see e-voting updates for FY2025-26*. Akums Drugs and Pharmaceuticals has issued a notice and integrated annual report for FY2025-26 to shareholders without registered email IDs. The move ensures compliance with SEBI’s e-voting and investor communication norms. Physical dispatch may lead to minor administrative costs. 📊 *STOCKS:* AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnnualReport

NSE Filing19 Jun
Low Impact

Akums announces 22nd AGM and final dividend details.

*Akums announces 22nd AGM and final dividend details.* The company has released an advertisement informing shareholders about the date and logistics of its 22nd Annual General Meeting. It also confirmed the disbursement of **final and special dividends**, details of which are outlined in the filing. Investors should watch for record and payment dates. 📊 *STOCKS:* AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend

NSE Filing16 Jun
Low Impact

Akums to host analyst and investor meet

*Akums to host analyst and investor meet* to discuss business updates and strategy. The company has scheduled an investor/analyst meeting, as per a regulatory filing. Such events often provide clarity on guidance and operational performance. No financial figures or major announcements were disclosed. 📊 *STOCKS:* AKUMS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

NSE Filing10 Jun
Low Impact

Financials

Quarterly Results

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue
₹1.2K Cr
0.2%
₹1.2K Cr
13.9%
₹1.0K Cr
0.6%
₹1.0K Cr
3.0%
₹1.1K Cr
4.6%
₹1.0K Cr
2.2%
₹1.0K Cr
1.4%
₹1.0K Cr
Op. Profit
₹152 Cr
3.4%
₹147 Cr
56.4%
₹94 Cr
27.1%
₹129 Cr
37.2%
₹94 Cr
22.3%
₹121 Cr
0.0%
₹121 Cr
5.5%
₹128 Cr
OPM
13.0%
0.0%
13.0%
44.4%
9.0%
30.8%
13.0%
44.4%
9.0%
25.0%
12.0%
0.0%
12.0%
7.7%
13.0%
Net Profit
₹81 Cr
19.1%
₹68 Cr
58.1%
₹43 Cr
33.8%
₹65 Cr
56.7%
₹150 Cr
127.3%
₹66 Cr
1.5%
₹67 Cr
9.8%
₹61 Cr
EPS (₹)
5.38
27.8%
4.21
62.5%
2.59
35.7%
4.03
57.0%
9.38
126.6%
4.14
0.0%
4.14
1.5%
4.08

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2016Mar 2015
Revenue
₹4.4K Cr
5.9%
₹4.1K Cr
1.4%
₹4.2K Cr
14.3%
₹3.7K Cr
0.5%
₹3.7K Cr
34.9%
₹2.7K Cr
12.8%
₹2.4K Cr
46.2%
₹1.7K Cr
12.8%
₹1.5K Cr
Expenses
₹3.8K Cr
5.0%
₹3.7K Cr
9.9%
₹4.1K Cr
20.6%
₹3.4K Cr
10.6%
₹3.8K Cr
51.3%
₹2.5K Cr
10.9%
₹2.2K Cr
48.6%
₹1.5K Cr
12.5%
₹1.3K Cr
Op. Profit
₹522 Cr
12.3%
₹465 Cr
278.0%
₹123 Cr
58.2%
₹294 Cr
430.3%
₹-89 Cr
137.4%
₹238 Cr
36.8%
₹174 Cr
20.8%
₹144 Cr
16.1%
₹124 Cr
OPM
12.0%
9.1%
11.0%
266.7%
3.0%
62.5%
8.0%
433.3%
-2.4%
126.7%
9.0%
28.6%
7.0%
22.2%
9.0%
12.5%
8.0%
Other Income
₹108 Cr
56.5%
₹69 Cr
762.5%
₹8 Cr
46.7%
₹15 Cr
114.3%
₹7 Cr
36.4%
₹11 Cr
57.7%
₹26 Cr
333.3%
₹6 Cr
0.0%
₹6 Cr
Interest
₹94 Cr
168.6%
₹35 Cr
31.4%
₹51 Cr
10.9%
₹46 Cr
170.6%
₹17 Cr
142.9%
₹7 Cr
65.0%
₹20 Cr
9.1%
₹22 Cr
4.3%
₹23 Cr
Depreciation
₹155 Cr
1.3%
₹153 Cr
21.4%
₹126 Cr
11.5%
₹113 Cr
18.9%
₹95 Cr
35.7%
₹70 Cr
4.5%
₹67 Cr
76.3%
₹38 Cr
22.6%
₹31 Cr
PBT
₹382 Cr
10.7%
₹345 Cr
866.7%
₹-45 Cr
130.0%
₹150 Cr
177.7%
₹-193 Cr
212.2%
₹172 Cr
50.9%
₹114 Cr
28.1%
₹89 Cr
15.6%
₹77 Cr
Tax %
33.0%
0.0%
100.0%
-102.0%
391.4%
35.0%
16.7%
30.0%
7.1%
28.0%
54.8%
62.0%
24.0%
50.0%
2.0%
51.0%
Net Profit
₹256 Cr
25.6%
₹344 Cr
34300.0%
₹1 Cr
99.0%
₹98 Cr
139.0%
₹-251 Cr
304.1%
₹123 Cr
179.5%
₹44 Cr
27.9%
₹61 Cr
41.9%
₹43 Cr
EPS (₹)
16.21
24.6%
21.49
7775.0%
-0.28
104.2%
6.63
118.8%
-35.3
103.7%
943.49
181.1%
335.61
35.9%
523.23
42.7%
366.55
Div Payout
18.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2016Mar 2015
Liabilities
Equity Capital
₹31 Cr
0.0%
₹31 Cr
6.9%
₹29 Cr
0.0%
₹29 Cr
107.1%
₹14 Cr
1300.0%
₹1 Cr
0.0%
₹1 Cr
0.0%
₹1 Cr
0.0%
₹1 Cr
Reserves
₹3.3K Cr
8.9%
₹3.0K Cr
342.9%
₹681 Cr
1.2%
₹689 Cr
13.3%
₹608 Cr
31.2%
₹884 Cr
22.6%
₹721 Cr
14.8%
₹628 Cr
27.4%
₹493 Cr
Borrowings
₹157 Cr
78.4%
₹88 Cr
84.4%
₹565 Cr
8.7%
₹619 Cr
56.7%
₹395 Cr
203.8%
₹130 Cr
25.7%
₹175 Cr
17.8%
₹213 Cr
16.5%
₹255 Cr
Other Liabilities
₹2.0K Cr
104.0%
₹960 Cr
56.9%
₹2.2K Cr
17.0%
₹1.9K Cr
6.3%
₹2.0K Cr
78.8%
₹1.1K Cr
0.3%
₹1.1K Cr
258.5%
₹318 Cr
8.5%
₹293 Cr
Total Liabilities
₹5.4K Cr
32.6%
₹4.1K Cr
16.9%
₹3.5K Cr
8.1%
₹3.2K Cr
6.3%
₹3.0K Cr
41.7%
₹2.2K Cr
5.6%
₹2.0K Cr
75.5%
₹1.2K Cr
11.4%
₹1.0K Cr
Assets
Fixed Assets
₹1.5K Cr
4.2%
₹1.4K Cr
17.3%
₹1.2K Cr
8.6%
₹1.1K Cr
7.4%
₹1.0K Cr
12.9%
₹904 Cr
40.2%
₹645 Cr
28.7%
₹501 Cr
12.8%
₹444 Cr
CWIP
₹177 Cr
8.6%
₹163 Cr
16.4%
₹195 Cr
89.3%
₹103 Cr
232.3%
₹31 Cr
82.4%
₹17 Cr
70.2%
₹57 Cr
418.2%
₹11 Cr
₹0 Cr
Investments
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
100.0%
₹20 Cr
233.3%
₹6 Cr
66.7%
₹18 Cr
₹0 Cr
Other Assets
₹3.8K Cr
49.7%
₹2.5K Cr
19.7%
₹2.1K Cr
3.8%
₹2.0K Cr
2.2%
₹2.0K Cr
64.9%
₹1.2K Cr
8.8%
₹1.3K Cr
110.3%
₹632 Cr
5.7%
₹598 Cr
Total Assets
₹5.4K Cr
32.6%
₹4.1K Cr
16.9%
₹3.5K Cr
8.1%
₹3.2K Cr
6.3%
₹3.0K Cr
41.7%
₹2.2K Cr
5.6%
₹2.0K Cr
75.5%
₹1.2K Cr
11.4%
₹1.0K Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2016Mar 2015
Operating CF
₹1.2K Cr
154.0%
₹465 Cr
6.6%
₹498 Cr
181.4%
₹177 Cr
453.1%
₹32 Cr
75.6%
₹131 Cr
367.9%
₹28 Cr
68.5%
₹89 Cr
23.6%
₹72 Cr
Investing CF
₹-930 Cr
69.7%
₹-548 Cr
65.6%
₹-331 Cr
8.5%
₹-305 Cr
29.8%
₹-235 Cr
115.6%
₹-109 Cr
42.6%
₹-190 Cr
54.5%
₹-123 Cr
18.0%
₹-150 Cr
Financing CF
₹34 Cr
53.4%
₹73 Cr
167.6%
₹-108 Cr
186.4%
₹125 Cr
47.0%
₹236 Cr
359.3%
₹-91 Cr
139.1%
₹233 Cr
529.7%
₹37 Cr
43.9%
₹66 Cr
Net Cash Flow
₹285 Cr
2950.0%
₹-10 Cr
116.9%
₹59 Cr
1575.0%
₹-4 Cr
112.1%
₹33 Cr
147.1%
₹-70 Cr
198.6%
₹71 Cr
1675.0%
₹4 Cr
136.4%
₹-11 Cr
Free Cash Flow
₹958 Cr
376.6%
₹201 Cr
5.2%
₹212 Cr
292.7%
₹-110 Cr
50.9%
₹-224 Cr
557.1%
₹49 Cr
244.1%
₹-34 Cr
0.0%
₹-34 Cr
56.4%
₹-78 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2016Mar 2015
Debtor Days
67d
1.5%
68d
6.8%
73d
13.1%
84d
4.5%
88d
23.9%
71d
19.3%
88d
54.4%
57d
16.2%
68d
Inventory Days
110d
7.8%
102d
13.3%
90d
23.1%
117d
4.5%
112d
20.4%
93d
6.1%
99d
13.9%
115d
0.9%
114d
Days Payable
87d
9.4%
96d
26.3%
76d
16.5%
91d
1.1%
92d
24.3%
74d
29.5%
105d
75.0%
60d
10.4%
67d
Cash Conv. Cycle
89d
20.3%
74d
14.9%
87d
21.6%
111d
1.8%
109d
21.1%
90d
9.8%
82d
26.8%
112d
2.6%
115d
Working Capital Days
66d
7.0%
71d
77.5%
40d
13.0%
46d
6.1%
49d
25.8%
66d
20.0%
55d
24.7%
73d
6.4%
78d
ROCE
15.0%
6.3%
16.0%
700.0%
2.0%
90.9%
22.0%
237.5%
-16.0%
180.0%
20.0%
14.0%

Source: Screener.in · Lower days = better efficiency

About Akums Drugs and Pharmaceuticals Limited

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

HealthcarePharmaceuticals & Biotechnology

Frequently Asked Questions

What is Akums Drugs and Pharmaceuticals Limited share price today?
Akums Drugs and Pharmaceuticals Limited (AKUMS) is currently trading at ₹765.75 on NSE, down 1.90% as of the last market session. Prices update daily after market close on MarketNetra.
Is Akums Drugs and Pharmaceuticals Limited available in F&O (Futures & Options)?
Yes, Akums Drugs and Pharmaceuticals Limited (AKUMS) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Akums Drugs and Pharmaceuticals Limited 52-week high and low?
Akums Drugs and Pharmaceuticals Limited's 52-week high is ₹797 and the 52-week low is ₹409. The current price of ₹765.75 is 3.9% below the 52W high.
What is Akums Drugs and Pharmaceuticals Limited P/E ratio?
Akums Drugs and Pharmaceuticals Limited's current P/E ratio is 39.5. This indicates the market is paying ₹39.5 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Akums Drugs and Pharmaceuticals Limited options?
Akums Drugs and Pharmaceuticals Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade AKUMS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.